Learn about Protearin™

Exciting new research into solutions for dry eye disease and corneal disorders

Millions of Americans suffer from dry eye disease, yet there is currently only a single FDA-approved drug to treat the disorder and this drug is useful only for certain forms of dry eye.

Protearin™ is based on the glycoprotein clusterin, a natural, protective component of fluid-tissue interfaces throughout the body. Protearin™ targets the final common end point for all forms of dry eye, i.e., damage at the ocular surface and disruption of the ocular surface barrier.